NeuroSense Therapeutics Reports 2023 Financials & Business Update
Ticker: NRSNW · Form: 6-K · Filed: Apr 5, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, business-update, press-release
TL;DR
NeuroSense dropped its 2023 financials and business update on 4/5/24. Check the press release.
AI Summary
NeuroSense Therapeutics Ltd. announced its year-end 2023 financial results and provided a business update via a press release on April 5, 2024. The company is incorporated in Israel and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with the latest financial performance and strategic direction of NeuroSense Therapeutics, a company focused on pharmaceutical development.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, NeuroSense Therapeutics is subject to the inherent risks of drug development, regulatory approvals, and market competition.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- April 5, 2024 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Press release attached to the filing
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report a press release issued by NeuroSense Therapeutics Ltd. on April 5, 2024, which contains its year-end 2023 financial results and a business update.
When were the financial results and business update announced?
The financial results and business update were announced on April 5, 2024.
What is the company's full name and where is it based?
The company's full name is NeuroSense Therapeutics Ltd., and its principal executive offices are located in Herzliya, Israel.
Which exhibit contains the press release information?
The press release, dated April 5, 2024, is attached as Exhibit 99.1 to this filing.
Does NeuroSense Therapeutics file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics indicates that it files annual reports under Form 20-F.
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-04-05 09:28:51
Filing Documents
- ea0203388-6k_neurosense.htm (6-K) — 10KB
- ea020338801ex99-1_neuro.htm (EX-99.1) — 57KB
- 0001213900-24-030635.txt ( ) — 67KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: April 5, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2